Cefalexinum - search results

sandoz pty ltd - cefalexin monohydrate, quantity: 52.576 mg/ml (equivalent: cefalexin, qty 50 mg/ml) - suspension, powder for - excipient ingredients: sodium benzoate; simethicone; iron oxide yellow; citric acid; sucrose; saccharin sodium; guar galactomannan; flavour - treatment of the following infections when caused by susceptible strains of the designated microorganisms. respiratory tract infections. caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present). bacterial sinusitis. caused by streptococci, s. pneumoniae and s. aureus (methicillin sensitive only). otitis media. due to s. pneumoniae, staphylococci. skin and skin structure infections. caused by staphylococci and/or streptococci. genitourinary tract infections, including acute prostatitis. caused by e. coli, p. mirabilis, and klebsiella sp. the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions. note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. renal function studies should be performed when indicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

cefalexin sandoz cefalexin (as monohydrate) 125mg/5ml powder for suspension bottle

sandoz pty ltd - cefalexin monohydrate, quantity: 26.288 mg/ml (equivalent: cefalexin, qty 25 mg/ml) - suspension, powder for - excipient ingredients: sodium benzoate; guar galactomannan; iron oxide yellow; saccharin sodium; citric acid; simethicone; sucrose; flavour - treatment of the following infections when caused by susceptible strains of the designated microorganisms. respiratory tract infections. caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present). bacterial sinusitis. caused by streptococci, s. pneumoniae and s. aureus (methicillin sensitive only). otitis media. due to s. pneumoniae, staphylococci. skin and skin structure infections. caused by staphylococci and/or streptococci. genitourinary tract infections, including acute prostatitis. caused by e. coli, p. mirabilis, and klebsiella sp. the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions. note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. renal function studies should be performed when indicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

cefalexin sandoz cefalexin (as monohydrate) 500mg capsule blister pack

sandoz pty ltd - cefalexin monohydrate, quantity: 525.76 mg (equivalent: cefalexin, qty 500 mg) - capsule, hard - excipient ingredients: magnesium stearate; microcrystalline cellulose; gelatin; purified water; titanium dioxide - treatment of the following infections when caused by susceptible strains of the designated microorganisms. respiratory tract infections. caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present). bacterial sinusitis. caused by streptococci, s. pneumoniae and s. aureus (methicillin sensitive only). otitis media. due to s. pneumoniae, staphylococci. skin and skin structure infections. caused by staphylococci and/or streptococci. genitourinary tract infections, including acute prostatitis. caused by e. coli, p. mirabilis, and klebsiella sp. the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions. note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. renal function studies should be performed when indicated.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

cefalexin 250mg capsules

flynn pharma ltd - cefalexin - oral capsule - 250mg